LPTX vs. PRPH, TNXP, FHTX, ALDX, TSVT, QURE, AKBA, PRLD, PYXS, and RANI
Should you be buying Leap Therapeutics stock or one of its competitors? The main competitors of Leap Therapeutics include ProPhase Labs (PRPH), Tonix Pharmaceuticals (TNXP), Foghorn Therapeutics (FHTX), Aldeyra Therapeutics (ALDX), 2seventy bio (TSVT), uniQure (QURE), Akebia Therapeutics (AKBA), Prelude Therapeutics (PRLD), Pyxis Oncology (PYXS), and Rani Therapeutics (RANI). These companies are all part of the "pharmaceutical preparations" industry.
ProPhase Labs (NASDAQ:PRPH) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, community ranking, profitability, risk and earnings.
ProPhase Labs has higher revenue and earnings than Leap Therapeutics. ProPhase Labs is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, ProPhase Labs had 1 more articles in the media than Leap Therapeutics. MarketBeat recorded 2 mentions for ProPhase Labs and 1 mentions for Leap Therapeutics. Leap Therapeutics' average media sentiment score of 1.24 beat ProPhase Labs' score of 1.19 indicating that ProPhase Labs is being referred to more favorably in the media.
9.5% of ProPhase Labs shares are owned by institutional investors. Comparatively, 30.5% of Leap Therapeutics shares are owned by institutional investors. 20.7% of ProPhase Labs shares are owned by insiders. Comparatively, 11.3% of Leap Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
ProPhase Labs has a beta of -0.17, indicating that its stock price is 117% less volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500.
Leap Therapeutics has a net margin of 0.00% compared to Leap Therapeutics' net margin of -82.18%. Leap Therapeutics' return on equity of -44.96% beat ProPhase Labs' return on equity.
ProPhase Labs presently has a consensus price target of $11.00, suggesting a potential upside of 113.59%. Leap Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 352.67%. Given ProPhase Labs' higher probable upside, analysts clearly believe Leap Therapeutics is more favorable than ProPhase Labs.
Leap Therapeutics received 176 more outperform votes than ProPhase Labs when rated by MarketBeat users. Likewise, 68.72% of users gave Leap Therapeutics an outperform vote while only 50.22% of users gave ProPhase Labs an outperform vote.
Summary
Leap Therapeutics beats ProPhase Labs on 9 of the 17 factors compared between the two stocks.
Get Leap Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LPTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Leap Therapeutics Competitors List
Related Companies and Tools
